We have shown that calcein-AM can be used in fresh leukemic cells to probe specifically both MRP and Pgp activities at the same time and that MRP and Pgp activities, using this functional test, are prognostic factors for achievement of CR. 3 However, the respective roles of both MRP and Pgp are unknown in AML. Therefore, we analyzed the functionality of both MRP and Pgp using calcein-AM uptake ± modulators of MRP (2 mm of probenecid) or of Pgp (2 m of cyclosporin A) in 34 adult AML patients. We compared these results with the effect of CsA and probenecid on calcein-AM uptake. All the 
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Effect and comparison of modulators on calcein-AM uptake: between probenecid and probenecid + CsA (P Ͻ 0.0001); between CsA and probenecid + CsA (P Ͻ 0.0001); between CsA and probenecid (P = 0.73). data were calculated as the ratio of cell fluorescence with modulator(s) divided by cell fluorescence without modulator after subtraction of the fluorescence of the control. The effect of probenecid and CsA together were higher than the effect of either probenecid or CsA alone on calcein-AM uptake (Figure 1 ). In addition, the difference between responders and patients with refractory disease, on calcein-AM uptake was higher when both probenecid and CsA were used together than when either probenecid or CsA was used alone (Table  1) . Therefore, when in the same cell Pgp and MRP were blocked, there was a higher retention of calcein-AM than when we used either CsA (a modulator of Pgp only) or probenecid (a modulator of MRP only) alone.
In the light of these results, Pgp function as well as MRP function are implicated in resistance to chemotherapy in AML patients. The concentrations of probenecid that reverse MRP function are clinically achievable in vivo, 4 without major toxicity. These results suggest that the effect of CsA and probenecid is additive and that this association could increase the percentage of complete remission.
